What is the efficacy of sorafenib in the treatment of renal cell carcinoma (RCC)?

Updated: Feb 19, 2021
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

The safety and efficacy of sorafenib were also demonstrated in a nonrandomized, open-label expanded access program in which 2504 patients from the United States and Canada were treated with oral sorafenib 400 mg twice daily. Patients included those with no previous therapy, nonclear cell renal cell carcinoma, brain metastases, and previous bevacizumab treatment; and elderly patients. Median overall survival was 50 weeks. [56]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!